Dr. Paolo Vincenzo Troia-cancio, M.D. Internal Medicine - Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 8110 Laguna Blvd, Elk Grove, CA 95758 Phone: 916-683-3955 Fax: 916-683-7290 |
News Archive
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas.
A 24-hour rhythm of cellular detoxification in flies and mammals is coordinated by a neuropeptide that also drives feeding in both organisms, found a team led by Amita Sehgal, PhD, a professor of Neuroscience and director of the Chronobiology Program, in the Perelman School of Medicine at the University of Pennsylvania.
Dr. Comerford is the President and CEO of the New Hope Foundation, a non-profit corporation dedicated to the treatment of alcoholism, drug addiction and compulsive gambling. The Foundation provides state-of-the-art care, with the ongoing certification of the Commission on Accreditation of Rehabilitation Facilities (CARF).
BioScrip, Inc. today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.
Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) Mellow Hope operating subsidiary is in process of finalizing contract details with Hetero Ltd., www.heterodrugs.com one of the largest pharmaceutical manufacturers in India. This contract has been in the works since March 2009, and its finalization promises solid sales boost for Hard to Treat Diseases.
› Verified 1 days ago